Original Article

Pancreatic Tumors in Patients with Lung Malignancies: A Spectrum of Clinicopathologic Considerations

Authors: Roderich E. Schwarz, MD, Peiguo G. Chu, MD, Frederic W. Grannis, Jr, MD

Abstract

Objectives: Lung cancer and pancreatic cancer are the most lethal tobacco-associated malignancies. To elucidate possible clinical interrelationships, the authors reviewed the clinicopathologic characteristics of patients treated for both pulmonary and pancreatic neoplasms.


Methods: Patients presenting with a potentially resectable pancreatic mass and a diagnosis of metachronous malignant neoplasm of the lung were studied by retrospective chart audit and review of histopathologic material.


Results: Seven patients were identified over 6 years, representing five different clinical entities: metachronous presence of lung cancer and pancreatic cancer (n = 3), lung cancer metastatic to the pancreas (n = 1), lung cancer with a benign pancreatic neoplasm (n = 1), periampullary cancer metastatic to the lung (n = 1), and malignant melanoma metastatic to both lung and pancreas (n = 1). A tobacco history was present in all patients but one. Primary treatment modality was complete resection of isolated sites whenever feasible (lung resection, n = 6; pancreatic resection, n = 5). In four cases, a differential diagnosis of adenocarcinomas of both lung and pancreas was obtained after cytokeratin (CK) 7 and CK 20 immunohistochemistry. All patients with evidence of nodal or visceral metastasis from either primary site (n = 4) died within 5 to 9 months after the last operation. Three of four patients who had undergone resection of both pulmonary and pancreatic tumors were alive between 17 and 67 months after the last operation. All three survivors had presented with early disease stages and/or a protracted course (diagnostic interval, 16–66 months).


Conclusions: Our experience with neoplastic conditions that can involve lungs and pancreas metachronously may be useful to the clinician who is confronted with a similar situation. If therapeutic decision-making depends on differential diagnostic analysis, examination of CK 20 expression appears to be helpful. Although biologically favorable circumstances are rarely present, long-term survival seems possible after complete operative treatment in selected patients with early-stage disease.


Key Points


* A spectrum of different disease mechanisms has been encountered in patients with metachronous lung and pancreas neoplasms.


* Analysis of cytokeratin 20 expression appears helpful in the differential diagnosis of lung and pancreatic cancer.


* After therapy of early-stage lung cancer, treatable pancreatic neoplasms may be identified.


* There is a risk of additional tobacco-associated malignancies in survivors of lung (or another tobacco-related) cancer.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Engeland A, Andersen A, Haldorsen T, et al. Smoking habits and risk of cancers other than lung cancer: 28 years' follow-up of 26,000 Norwegian men and women. Cancer Causes Control 1996;7:497–506.
 
2. Gold EB. Epidemiology of and risk factors for pancreatic cancer. Surg Clin North Am 1995;75:819–843.
 
3. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5–26.
 
4. Neugut AI, Ahsan H, Robinson E. Pancreas cancer as a second primary malignancy: a population-based study. Cancer 1995;76:589–592.
 
5. Epstein LM, Katz L, Tamir A, et al. Incidence of lung cancer in five towns in Israel, 1960–74. Isr J Med Sci 1984;20:27–32.
 
6. Darby SC, Whitley E, Howe GR, et al. Radon and cancers other than lung cancer in underground miners: a collaborative analysis of 11 studies. J Natl Cancer Inst 1995;87:378–384.
 
7. Price TF, Payne RL, Oberleitner MG. Familial pancreatic cancer in south Louisiana. Cancer Nurs1996;19:275–282.
 
8. Maeno T, Satoh H, Ishikawa H, et al. Patterns of pancreatic metastasis from lung cancer. Anticancer Res 1998;18:2881–2884.
 
9. Barz H, Barz D, Klemm P. Distribution of lung cancer metastases: I. combination and frequency of organ metastases [in German]. Arch Geschwulstforsch 1982;52:551–560.
 
10. Matsuno S, Kato S, Kobari M, et al. Clinicopathological study on hematogenous metastasis of pancreatic cancer. Jpn J Surg 1986;16:406–411.
 
11. Mattsson B, Rutqvist LE. Some aspects on validity of breast cancer, pancreatic cancer and lung cancer registration in Swedish official statistics. Radiother Oncol 1985;4:63–70.
 
12. Doring C, Lindlar F. Clinically a primary lung carcinoma: during autopsy metastasis of a pancreatic cancer [in German]. Med Welt 1969;8:407–411.
 
13. Mishriki YY. Pancreatic carcinoma presenting as primary lung cancer. Postgrad Med 1990;87:107–108.
 
14. Johnson DH, Hainsworth JD, Greco FA. Extrahepatic biliary obstruction caused by small-cell lung cancer. Ann Intern Med 1985;102:487–490.
 
15. Yapp RG, Siegel JH. Unexplained biliary tract dilatation in lung cancer patients. Endoscopy1992;24:593–595.
 
16. Onuigbo WI. Lung cancer metastasis to the pancreas and its surrounding lymph nodes. Br J Dis Chest 1966;60:152–155.
 
17. Inagaki H, Nakao A, Ando N, et al. A case of solitary metastatic pancreatic cancer from rectal carcinoma: a case report. Hepatogastroenterology 1998;45:2413–2417.
 
18. Ghoneim AH, Brisson ML, Fuks A, et al. Monoclonal anti-CEA antibodies in the discrimination between primary pulmonary adenocarcinoma and colon carcinoma metastatic to the lung. Mod Pathol1990;3:613–618.
 
19. Sheahan K, O'Brien MJ, Burke B, et al. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Am J Clin Pathol 1990;94:157–164.
 
20. Loy TS, Sharp SC, Andershock CJ, et al. Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas: an immunohistochemical study of 527 cases. Am J Clin Pathol1993;99:726–728.
 
21. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer 1999;85:171–177.
 
22. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology2002;40:403–439.
 
23. Harlamert HA, Mira J, Bejarano PA, et al. Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma. Acta Cytol 1998;42:1382–1388.
 
24. Khoor A, Whitsett JA, Stahlman MT, et al. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 1999;30:695–700.
 
25. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol 2002;10:97–102.
 
26. Seki M, Tsuchiya E, Hori M, et al. Pancreatic metastasis from a lung cancer: preoperative diagnosis and management. Int J Pancreatol 1998;24:55–59.
 
27. Luketich JD, Martini N, Ginsberg RJ, et al. Successful treatment of solitary extracranial metastases from non-small cell lung cancer. Ann Thorac Surg 1995;60:1609–1611.
 
28. Kim SH, Brennan MF, Russo P, et al. The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer 1998;82:389–394.
 
29. Harrison LE, Merchant N, Cohen AM, et al. Pancreaticoduodenectomy for nonperiampullary primary tumors. Am J Surg 1997;174:393–395.
 
30. Janes R Jr, Niederhuber JE, Chmiel JS, et al. National patterns of care for pancreatic cancer: results of a survey by the Commission on Cancer. Ann Surg 1996;223:261–272.
 
31. Velie EM, Schatzkin, A. Common environmental risk factors, in Neugut AI, Meadows AT, Robinson E (eds): Multiple Primary Cancers. Philadelphia, Lippincott Williams & Wilkins, 1999, pp 213–223.
 
32. Naunheim KS, Virgo KS, Coplin MA, et al. Clinical surveillance testing after lung cancer operations.Ann Thorac Surg 1995;60:1612–1616.
 
33. Younes RN, Gross JL, Deheinzelin D. Follow-up in lung cancer: how often and for what purpose?Chest 1999;115:1494–1499.
 
34. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120–129.
 
35. Martini N, Rusch VW, Bains MS, et al. Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer. J Thorac Cardiovasc Surg 1999;117:32–38.
 
36. Lamont JP, Kakuda JT, Smith D, et al. Systematic postoperative radiologic follow-up in patients with non-small cell lung cancer for detecting second primary lung cancer in stage IA. Arch Surg2002;137:935–940.
 
37. Okada S, Yoshimori M, Kakizoe T. Pancreatic cancer: medical aspects. Pancreas 1998;16:349–354.
 
38. Macari M, Rofsky NM, Naidich DP, et al. Non-small cell lung carcinoma: usefulness of unenhanced helical CT of the adrenal glands in an unmonitored environment. Radiology 1998;209:807–812.